Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $10.00 price objective on the stock. Zacks Investment Research’s target price would suggest a potential upside of 8.34% from the stock’s previous close.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

KPTI has been the subject of a number of other research reports. Vetr cut shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating and set a $11.00 target price for the company. in a research report on Wednesday, August 31st. Leerink Swann reiterated an “outperform” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, October 7th. S&P Equity Research dropped their target price on shares of Karyopharm Therapeutics from $9.06 to $7.55 in a research report on Tuesday, August 30th. Jefferies Group upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the stock from $9.00 to $12.00 in a research report on Tuesday, August 30th. Finally, Wedbush reiterated an “outperform” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $15.40.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.75% during mid-day trading on Wednesday, hitting $9.23. The firm’s 50-day moving average is $8.72 and its 200 day moving average is $8.35. The company’s market capitalization is $380.67 million. Karyopharm Therapeutics has a 1-year low of $4.83 and a 1-year high of $19.38.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.12. Equities analysts predict that Karyopharm Therapeutics will post ($3.00) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Karyopharm Therapeutics Inc. (KPTI) to “Buy”” was first published by Daily Political and is the propert of of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece can be accessed at http://www.dailypolitical.com/2016/11/30/zacks-investment-research-upgrades-karyopharm-therapeutics-inc-kpti-to-buy.html.

In other news, insider Ran Frenkel sold 3,309 shares of the firm’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $10.06, for a total value of $33,288.54. Following the transaction, the insider now owns 14,691 shares of the company’s stock, valued at approximately $147,791.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.79% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in Karyopharm Therapeutics by 631.9% in the first quarter. Wellington Management Group LLP now owns 1,269,485 shares of the company’s stock valued at $11,323,000 after buying an additional 1,096,029 shares during the last quarter. Bank of New York Mellon Corp raised its position in Karyopharm Therapeutics by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 101,558 shares of the company’s stock valued at $682,000 after buying an additional 4,173 shares during the last quarter. Swiss National Bank raised its position in Karyopharm Therapeutics by 7.3% in the second quarter. Swiss National Bank now owns 36,850 shares of the company’s stock valued at $247,000 after buying an additional 2,500 shares during the last quarter. JPMorgan Chase & Co. raised its position in Karyopharm Therapeutics by 29.2% in the second quarter. JPMorgan Chase & Co. now owns 361,979 shares of the company’s stock valued at $2,428,000 after buying an additional 81,773 shares during the last quarter. Finally, New Leaf Venture Partners L.L.C. raised its position in Karyopharm Therapeutics by 1,723.5% in the second quarter. New Leaf Venture Partners L.L.C. now owns 222,947 shares of the company’s stock valued at $1,496,000 after buying an additional 210,721 shares during the last quarter. 56.26% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Get a free copy of the Zacks research report on Karyopharm Therapeutics (KPTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.